DCN - Clinical Study, page-12

Hi Stock and others.

Although i'm a new and have an insignificant holding in ADO, I have seen (and spent timemand money on) other companies try and tackle the dianogostic market...(see SPL, PVA and prior to folding 'Ambri Biosensor')

what i have learnt...is that it is really really really hard to convince the big end of town that your propeitary tech has a convincing value proposition.

The difficulty might even be able to be quantified...say, via the average R&D spend of big end of town (maybe several 10's-100s of Millions)

The advantage (IMO, and why I invested) is a small Australian player is can be nimble in its approach to commercialisation.

however, i appreciate that such 'nimbleness' comes at the expense of focused approach to cashflow positive / sustainable use of shareholder funds....

just my 4.9 cents worth..

bperak